Clinical Trial Update: A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) [Phase 1, Phase 2]

View source ↗

Summary

LIBRETTO-001 is a Phase 1/2 trial of selpercatinib in RET fusion–positive advanced solid tumors, including non-small cell lung cancer and medullary thyroid carc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Medullary Thyroid Carcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• RETEVMO (selpercatinib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Non-Small Cell Lung Cancer, Medullary Thyroid Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-04-16